anticoagulant, curative dose - versus control - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.08 [0.85, 1.38]< 10%1 study (1/-)26.7 %some concernnot evaluable moderatecrucial-
clinical improvement 0.83 [0.67, 1.03]> 10%1 study (1/-)4.5 %some concernnot evaluable moderateimportant-
Major thrombotic events or death 1.04 [0.80, 1.36]< 10%1 study (1/-)38.7 %some concernnot evaluable moderatenon important-

safety endpoints 00

Major bleeding 1.48 [0.74, 2.98]< 10%1 study (1/-)13.6 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.